Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjectsDario Cattaneo, Emilio Clementi, Cristina Gervasoni et al.|Journal of Antimicrobial Chemotherapy|2011Cited by 58
Low Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse EventsCristina Gervasoni, Dario Cattaneo, Paola Meraviglia et al.|PLoS ONE|2013Cited by 42
Comparison of the <i>In Vivo</i> Pharmacokinetics and <i>In Vitro</i> Dissolution of Raltegravir in HIV Patients Receiving the Drug by Swallowing or by ChewingDario Cattaneo, Cristina Gervasoni, Sara Baldelli et al.|Antimicrobial Agents and Chemotherapy|2012Cited by 36
Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages?Cristina Gervasoni, Dario Cattaneo, Paola Meraviglia et al.|PLoS ONE|2015Cited by 28
Pillars of long-term antiretroviral therapy successLucia Taramasso, Franco Maggiolo, Sergio Lo Caputo et al.|Pharmacological Research|2023Cited by 22